GET DAILY SIGNALSHims & Hers Health (HIMS): Can Shares Reach the $31 Analyst Target (+35% Potential)?
Key Takeaways
- The central price target of $31 is the arithmetic mean of the verified analyst targets reviewed, closely matching the widely cited S&P Global average of roughly $31 across 15 analysts.
- At a latest verified close near $22.94, HIMS would need to climb roughly 35% to reach $31 — a very large move.
- The analyst target range is unusually wide, from about $23 to $42, reflecting deep disagreement over the company's weight-loss opportunity and its deteriorating profit margins.
- Key supports include rapid revenue growth (up about 49% year over year in the third quarter), nearly 2.8 million subscribers, and branded GLP-1 partnerships with Eli Lilly and Novo Nordisk.
- The biggest risks are gross-margin compression, a third-quarter loss versus an expected profit, lowered 2026 EBITDA guidance, and regulatory and legal overhangs, including an FTC lawsuit.
- For more detail on the company's Major News, Today's Price Move, Forecast, and Earnings, visit these dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading tools are tracking opportunities across the market.
Analyst Consensus on Price Targets
Hims & Hers Health, Inc. operates a telehealth platform linking consumers with licensed professionals in the U.S. and abroad. The $31 central target represents the arithmetic mean of current analyst estimates and aligns closely with the roughly $31 one-year average from S&P Global covering 15 analysts.
Individual targets show some clustering but also divergence. Recent verified figures include Barclays at $35, Bank of America and Truist at $32 each, J.P. Morgan at $32, Jefferies at $31, TD Cowen at $30, and Deutsche Bank at $26. The full range runs from about $23 to $42, highlighting differing views on the weight-loss segment and margin trends.
Ratings have fluctuated. Citigroup and Bank of America moved from Sell and Underperform to Neutral in March, while J.P. Morgan started coverage with an Overweight rating. Barclays lowered its target from $39 to $35, and Morgan Stanley had cut its figure sharply to $21 earlier. Most firms maintain Hold-equivalent ratings, with a few still at Buy.
Current Levels and the Path to $31
After a sharp selloff in early November 2026, the stock sits near $22.94. Reaching the $31 target would require a gain of roughly 35%, a substantial move by recent standards. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
The route to that level hinges on proving that the fast-growing weight-loss business can deliver sustainable profits. Third-quarter revenue rose about 49% year over year to roughly $890 million, with subscribers approaching 2.8 million. Yet the quarter produced a loss of about $0.14 per share versus expectations for a modest profit, and gross margins declined as lower-margin GLP-1 revenue displaced higher-margin offerings. Management also reduced its full-year adjusted EBITDA guidance, weighing on the shares.
Factors That Could Support Higher Prices
- Rapid revenue expansion led by weight-loss offerings, with international sales growing at triple-digit rates.
- Branded partnerships with Eli Lilly and Novo Nordisk that lessen dependence on compounded GLP-1 products and expand the market opportunity.
- New products such as testosterone treatments and an AI-powered women’s health app that diversify the portfolio.
- A solid cash position and ongoing subscriber growth that support longer-term visibility.
Risks That Could Limit Upside
- Ongoing gross-margin pressure as pharmacy-style GLP-1 sales replace higher-margin telehealth revenue.
- Return to losses and reduced 2026 EBITDA guidance, which weakens the profitability outlook.
- Regulatory and legal concerns, including an FTC lawsuit over privacy and billing practices, FDA oversight of compounded GLP-1 medications, and multiple securities investigations.
- Strong competition in weight loss, pricing pressure, short interest near 25% of float, and a beta around 2.5 that heightens volatility.
Technical Levels to Watch
The stock trades in a broad 52-week range of roughly $13.74 to $42.70. The area near $23 has emerged as near-term support after the November drop, while the prior close around $26 and the $30-to-$32 zone—home to several analyst targets—act as resistance overhead. The $42.70 high remains a significant longer-term barrier before more optimistic targets become realistic.
Key Items for Investors to Monitor
Analyst targets generally cover a 12-month horizon, though horizons vary by firm. I’m watching quarterly results and guidance, margin trends, subscriber and GLP-1 data, target revisions, and regulatory updates from the FDA and FTC. Progress on branded partnerships and any settlements in ongoing legal matters will also matter.
AI Daily Buy/Sell Signals
In my research process, Tickeron’s AI Daily Buy/Sell Signals help track momentum shifts across thousands of stocks and ETFs by combining technical patterns with AI analysis. For a volatile name like this, the signals offer a practical way to spot potential changes in trend without manual chart scanning, which can be especially useful when monitoring fast-moving developments.
Final Assessment
The $31 target, derived from the average of current analyst estimates and spanning roughly $23 to $42, sits about 35% above recent prices and represents an ambitious objective. Achieving it would likely require reversing margin compression, restoring profitability, and addressing regulatory uncertainties while maintaining strong revenue growth. The wide spread in analyst views reflects real questions about whether the weight-loss focus will ultimately support or pressure earnings. The target serves as a reference rather than a guarantee, and the overall picture remains balanced.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HIMS in +5.63% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in 240 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 66 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 36 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for HIMS entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.719) is normal, around the industry mean (6.379). P/E Ratio (-41.935) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Advertisement